METTL3 and colon adenocarcinoma: J. OH33 reported that the decreased METTL3 expression leads to reduced SRSF11 expression in breast cancer (BRCA), Colon adenocarcinoma (COAD), lung adenocarcinoma (LUAD), and stomach adenocarcinomas (STAD).